Back to top

Analyst Blog

Synageva BioPharma Corp. (GEVA - Snapshot Report) announced that sebelipase alfa met the primary endpoint in a randomized, double-blind, placebo-controlled phase III study (Acid Lipase Replacement Investigating Safety and Efficacy − ARISE). Sebelipase alfa showed statistically significant normalization of alanine aminotransferase (ALT) (a measure of liver injury) in patients suffering from lysosomal acid lipase deficiency (LAL deficiency).

In this study, 66 patients suffering from LAL deficiency were randomized to sebelipase alfa (1 mg/kg) or placebo. This was above Synageva’s original target of 50 patients. The patients were diagnosed with multiple clinically important abnormalities at baseline.

Following 20 weeks of treatment, sebelipase alfa significantly reduced LDL cholesterol, non-HDL cholesterol and triglycerides, while increasing HDL cholesterol compared to placebo. This led to improvement in dyslipidemia in patients.

Additionally, 63% of the patients (whose paired liver biopsies were available both at baseline and at 20 weeks) treated with sebelipase alfa achieved improvement in hepatic steatosis compared to 40% of the patients treated with placebo.

Sebelipase alfa is Synageva’s lead pipeline candidate. It enjoys orphan drug status in the U.S., EU and Japan. Moreover, it has fast track designation in the U.S. as well as Breakthrough Therapy designation (LAL deficiency in infants).

Sebelipase alfa being the lead candidate at Synageva, its successful development and approval would be a major boost for the company. We expect investor focus to remain on pipeline updates from the company. The company intends to file marketing applications in the U.S. and Europe for sebelipase alfa by the end of the first quarter of 2015.

Synageva carries a Zacks Rank #2 (Buy). Some better-ranked stocks in the biotech sector include Biogen Idec Inc. (BIIB - Analyst Report), The Medicines Company (MDCO - Analyst Report) and Regeneron Pharmaceuticals, Inc. (REGN - Analyst Report). All these stocks carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 22.53 +4.50%
ERBA DIAGNO… ERB 2.91 +4.30%
PLANAR SYST… PLNR 4.31 +3.86%
MALLINCKROD… MNK 72.17 +3.83%
GTT COMMUNI… GTT 12.06 +3.52%